Effects of first‑line therapies in patients with locally advanced gastrointestinal stromal tumors with <i>KIT</i> and <i>PDGFRα</i> gene mutations: A single‑center study.

ABSTRACT: Curative resection is typically recommended for treating gastrointestinal stromal tumors (GISTs). Exceptions are made for locally advanced GISTs (LAGISTs) where radical resection may be impossible. First-line imatinib therapy can be employed to treat GISTs harboring mutations in the tyrosine-protein kinase KIT (KIT) and platelet-derived growth factor receptor α (PDGFRα) genes to reduce the tumor size to resectable levels and minimize surgical risks. The present study investigated the treatment outcomes of patients with LAGISTs with different KIT and PDGFRα gene mutations who received first-line imatinib therapy. A total of 37 patients with LAGISTs who underwent first-line imatinib treatment were included, and the median follow-up period was 41 months. Treatment

SUBMITTER: Su WC 

PROVIDER: S-EPMC12018793 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature